Seif Bugazia, M. Boshnaf, Mohammad Elbahnasawy, Mostafa Shehata, Fadel Alqatati, K. Ragab, A. Elsnhory, S. Elsayed, Mustafa Ali Fathy, A. Nourelden
{"title":"替特米胰岛素与中性鱼精蛋白Hagedorn治疗妊娠期糖尿病的新生儿和产妇结局","authors":"Seif Bugazia, M. Boshnaf, Mohammad Elbahnasawy, Mostafa Shehata, Fadel Alqatati, K. Ragab, A. Elsnhory, S. Elsayed, Mustafa Ali Fathy, A. Nourelden","doi":"10.2174/1573404819666220621092340","DOIUrl":null,"url":null,"abstract":"\n\nDiabetes in pregnancy can lead to severe neonatal and maternal adverse events. Moreover, there is an increase in GDM prevalence. Therefore, we aimed to compare insulin detemir (IDet) with the neutral protamine Hagedorn (NPH) in diabetic pregnant women.\n\n\n\nWe searched four electronic databases until August 2021: PubMed, Scopus, Web of Science, and Cochrane. We included randomized controlled studies that compared IDet with NPH in diabetic pregnant women. We extracted both maternal and neonatal outcomes, and used RevMan software to conduct the analysis.\n\n\n\nA number of five studies were included. The analysis showed a significantly lower risk of hypoglycemic events during pregnancy in the IDet group than the NPH group [RR=0.6, 95% CI [0.43, 0.84], p=0.003], and a higher gestational age (GA) at delivery in the IDet group than the NPH group [MD= 0.28, 95% [0.02, 0.55], p=0.03]. On the other hand, the analysis revealed non-significant differences between IDet and NPH in terms of birth weight, congenital anomalies, neonatal hypoglycemia, preterm delivery, and others.\n\n\n\nInsulin detemir (IDet) was preferred over neutral protamine Hagedorn (NPH) in terms of showing lower rates of hypoglycemic events during pregnancy and a higher gestational age at delivery. Meanwhile, there were non-significant variations between them when it comes to neonatal outcomes, such as weight at birth, congenital anomalies, or neonatal hypoglycemia.\n","PeriodicalId":371340,"journal":{"name":"Current Womens Health Reviews","volume":"13 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Neonatal and Maternal Outcomes of Insulin Detemir versus Neutral Protamine Hagedorn for Diabetes Mellitus in Pregnancy\",\"authors\":\"Seif Bugazia, M. Boshnaf, Mohammad Elbahnasawy, Mostafa Shehata, Fadel Alqatati, K. Ragab, A. Elsnhory, S. Elsayed, Mustafa Ali Fathy, A. Nourelden\",\"doi\":\"10.2174/1573404819666220621092340\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nDiabetes in pregnancy can lead to severe neonatal and maternal adverse events. Moreover, there is an increase in GDM prevalence. Therefore, we aimed to compare insulin detemir (IDet) with the neutral protamine Hagedorn (NPH) in diabetic pregnant women.\\n\\n\\n\\nWe searched four electronic databases until August 2021: PubMed, Scopus, Web of Science, and Cochrane. We included randomized controlled studies that compared IDet with NPH in diabetic pregnant women. We extracted both maternal and neonatal outcomes, and used RevMan software to conduct the analysis.\\n\\n\\n\\nA number of five studies were included. The analysis showed a significantly lower risk of hypoglycemic events during pregnancy in the IDet group than the NPH group [RR=0.6, 95% CI [0.43, 0.84], p=0.003], and a higher gestational age (GA) at delivery in the IDet group than the NPH group [MD= 0.28, 95% [0.02, 0.55], p=0.03]. On the other hand, the analysis revealed non-significant differences between IDet and NPH in terms of birth weight, congenital anomalies, neonatal hypoglycemia, preterm delivery, and others.\\n\\n\\n\\nInsulin detemir (IDet) was preferred over neutral protamine Hagedorn (NPH) in terms of showing lower rates of hypoglycemic events during pregnancy and a higher gestational age at delivery. Meanwhile, there were non-significant variations between them when it comes to neonatal outcomes, such as weight at birth, congenital anomalies, or neonatal hypoglycemia.\\n\",\"PeriodicalId\":371340,\"journal\":{\"name\":\"Current Womens Health Reviews\",\"volume\":\"13 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Womens Health Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1573404819666220621092340\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Womens Health Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573404819666220621092340","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
妊娠期糖尿病可导致严重的新生儿和孕产妇不良事件。此外,GDM患病率也有所增加。因此,我们的目的是比较胰岛素det (IDet)和中性鱼精蛋白Hagedorn (NPH)在糖尿病孕妇中的作用。到2021年8月,我们检索了四个电子数据库:PubMed、Scopus、Web of Science和Cochrane。我们纳入了随机对照研究,比较了糖尿病孕妇的IDet和NPH。我们提取了孕产妇和新生儿结局,并使用RevMan软件进行分析。其中包括五项研究。分析显示,IDet组妊娠期低血糖事件发生风险明显低于NPH组[RR=0.6, 95% CI [0.43, 0.84], p=0.003],分娩时胎龄(GA)高于NPH组[MD= 0.28, 95% [0.02, 0.55], p=0.03]。另一方面,分析显示IDet和NPH在出生体重、先天性异常、新生儿低血糖、早产等方面无显著差异。在妊娠期间低血糖事件发生率较低和分娩时胎龄较高方面,det优于中性鱼精蛋白Hagedorn (NPH)。与此同时,在新生儿结局方面,如出生体重、先天性异常或新生儿低血糖,两者之间没有显著差异。
Neonatal and Maternal Outcomes of Insulin Detemir versus Neutral Protamine Hagedorn for Diabetes Mellitus in Pregnancy
Diabetes in pregnancy can lead to severe neonatal and maternal adverse events. Moreover, there is an increase in GDM prevalence. Therefore, we aimed to compare insulin detemir (IDet) with the neutral protamine Hagedorn (NPH) in diabetic pregnant women.
We searched four electronic databases until August 2021: PubMed, Scopus, Web of Science, and Cochrane. We included randomized controlled studies that compared IDet with NPH in diabetic pregnant women. We extracted both maternal and neonatal outcomes, and used RevMan software to conduct the analysis.
A number of five studies were included. The analysis showed a significantly lower risk of hypoglycemic events during pregnancy in the IDet group than the NPH group [RR=0.6, 95% CI [0.43, 0.84], p=0.003], and a higher gestational age (GA) at delivery in the IDet group than the NPH group [MD= 0.28, 95% [0.02, 0.55], p=0.03]. On the other hand, the analysis revealed non-significant differences between IDet and NPH in terms of birth weight, congenital anomalies, neonatal hypoglycemia, preterm delivery, and others.
Insulin detemir (IDet) was preferred over neutral protamine Hagedorn (NPH) in terms of showing lower rates of hypoglycemic events during pregnancy and a higher gestational age at delivery. Meanwhile, there were non-significant variations between them when it comes to neonatal outcomes, such as weight at birth, congenital anomalies, or neonatal hypoglycemia.